Breaking Down By-health Co., Ltd. Financial Health: Key Insights for Investors

Investors eyeing BY-HEALTH Co., Ltd. (300146.SZ) face a mixed snapshot: Q1 2025 revenue plunged 32.29% year‑on‑year to RMB 1.79 billion (H1 2025 operating revenue fell 23.43% to RMB 3.5 billion), driven by a sharp 42.62% decline in offline channel sales to RMB 988 million and a 15.78% drop in online sales to RMB 766 million as flagship SKUs (protein powder and Keylid) slid 36.37% and 46.15% respectively; profitability weakened with net profit attributable to shareholders down 37.44% to RMB 454.5 million and net margin around 25.37% despite a healthy gross margin of 68.66%, while trailing twelve‑month ROE dipped to 3.26% from 5.9%; liquidity remains a buffer with total cash of RMB 5.6 billion even as free cash flow contracted 52.1% to $380.19 million in FY2024; valuation shows investors pricing future growth at a premium (trailing P/E 51.82, forward P/E 20.73, P/S 3.24) against a market cap of CN¥19.39 billion, and strategic moves-such as the $30 million acquisition of a 60% stake in a South Korean brand (projected to lift Asian market share by 15%), expansion into Southeast Asia, OTC launches, and intensified online retail initiatives-underscore both the risks from intensified competition and offline footfall declines and the potential levers for recovery.

By-health Co., Ltd. (300146.SZ) Revenue Analysis

• Q1 2025 total revenue: RMB 1.79 billion (down 32.29% YoY from RMB 2.65 billion).
• H1 2025 operating revenue: RMB 3.50 billion (down 23.43% YoY).
• Offline channel sales in Q1 2025: RMB 988 million (down 42.62% YoY).
• Online channel sales in Q1 2025: RMB 766 million (down 15.78% YoY).
• Flagship SKU performance in Q1 2025: Protein powder sales down 36.37%; Keylid sales down 46.15%.

• Primary drivers: intensified market competition, reduced offline pharmacy footfall, weaker demand for major SKUs.
• Management response: refocus on online retail strategies, channel optimization, and marketing for core brands.

By-health Co., Ltd. (300146.SZ) - Profitability Metrics

• Net profit attributable to shareholders: RMB 454.5 million in Q1 2025, down 37.44% YoY from RMB 726.6 million.
• Net profit margin: ~25.37% in Q1 2025, a significant decline year-on-year.
• Gross profit margin: 68.66% in Q1 2025, a slight improvement versus the prior quarter.
• Return on equity (TTM ending Jun 2025): 3.26%, down from 5.9% a year earlier.
• Main drivers: increased competition and reduced sales in key channels; company pursuing cost-cutting and operational efficiencies.

• Near-term management actions under discussion or implementation:
  • Targeted cost reductions across supply chain and SG&A.
  • SKU rationalization and channel focus to protect margins.
  • Operational efficiency measures aimed at restoring ROE toward historical levels.

By-health Co., Ltd. (300146.SZ) - Debt vs. Equity Structure

• Debt disclosure: formal debt-to-equity ratio not publicly disclosed as of June 2025.
• Financing strategy: preference for equity financing to preserve financial flexibility and credit headroom.
• Capital discipline: management monitors debt levels to keep leverage manageable and liquidity robust.

• Operational impact: equity-funded M&A reduces near-term interest burden and preserves operating cash flow for R&D, marketing, and distribution scaling.
• Investor considerations: lack of a disclosed debt/equity ratio requires investors to review cash, short-term borrowings, and notes in financial statements and management commentary for leverage insight.
• Strategic benefit: the 2022 equity-funded acquisition supports a projected 15% Asia market-share uplift while maintaining low financial leverage.

By-health Co., Ltd. (300146.SZ) - Liquidity and Solvency

• Total cash of RMB 5.6 billion (as of 31 Mar 2025) underpins short-term liquidity and emergency coverage.
• Free cash flow collapsed to US$380.19 million in FY2024, a 52.1% decline, signaling stress on operating cash generation.
• Management cites reduced profitability and rising operational costs as primary drivers of FCF deterioration.
• Current ratio is not available publicly, limiting precision in short-term solvency assessment.
• Company initiatives emphasize operational efficiency and cost management to restore and improve cash flow.

• The RMB 5.6 billion cash stock mitigates immediate liquidity risk and offers flexibility for capex, working capital, or strategic moves.
• A >50% drop in FCF increases sensitivity to further margin compression or unexpected cash outflows.
• Absent a disclosed current ratio, monitor working-capital trends, receivables, inventory turns, and short-term debt maturities for solvency signals.
• Progress on cost-control and efficiency programs will be the primary near-term catalyst to stabilize cash generation.

By-health Co., Ltd. (300146.SZ) - Valuation Analysis

• High trailing P/E (51.82) signals recent earnings were weak relative to price or that investors are pricing in future margin expansion.
• Forward P/E (20.73) compresses substantially versus trailing P/E - implies analysts expect meaningful EPS improvement over the next 12 months.
• P/S of 3.24 and EV/Rev 2.40 show revenue is being valued at a premium but not excessively stretched for a growth consumer company.
• EV/EBITDA at 22.27 indicates valuation relies on profit recovery; any failure to deliver margin/EBITDA growth could pressure multiples.

• Relative risks: high sensitivity to execution on product mix, channel profitability, and supply/SG&A control given the premium paid for earnings recovery.
• Relative opportunities: if revenue growth and margin expansion materialize as anticipated, forward multiples support upside in market cap and investor returns.

By-health Co., Ltd. (300146.SZ) - Risk Factors

• Intensified competition from both domestic and international brands

• Declining footfall in offline pharmacies affects sales performance

• Concentration in the Chinese market exposes the company to regional economic fluctuations

• Operational challenges in expanding international markets, particularly in Southeast Asia

• Regulatory changes in the dietary supplement industry

• Supply chain disruptions may impact product availability and costs

• Revenue growth variability: recent YoY revenue swings and a potential 2023 revenue decline vs. 2022 indicate sensitivity to channel shifts.
• Profitability pressure: compression in gross and operating margins from promotions, higher marketing/R&D and regulatory compliance costs.
• Working capital strain: higher inventory days during channel shifts or supply disruption can increase cash conversion cycle.
• Leverage: although historically net-debt levels have been moderate, any capital-intensive international push or M&A could raise leverage ratios.

By-health Co., Ltd. (300146.SZ) - Growth Opportunities

• Regional expansion: existing distribution in Singapore, Malaysia, Vietnam, and Thailand, with planned market entry into Indonesia to capture a combined Southeast Asian population exceeding 650 million.
• Product diversification: increased focus on infant & children's nutrition plus rollout of over-the-counter (OTC) nutraceuticals such as glucosamine sulfate capsules to broaden margins and retail shelf presence.
• Innovation pipeline: partnerships with research institutions on anti‑aging formulations that could create higher-margin, patentable SKUs.
• Omnichannel retailing: enhanced interest-based e-commerce, livestreaming, and social commerce to convert brand equity into higher direct-to-consumer (DTC) sales and improved customer LTV.

• Geographic rollout sequencing: prioritize Singapore/Malaysia for brand validation, scale Vietnam/Thailand for volume, and launch Indonesia via e-commerce + local distributor partnerships to minimize upfront capex.
• Portfolio strategy: push higher-margin infant nutrition and OTC lines while maintaining flagship health supplements to preserve brand breadth.
• Channel mix optimization: increase live‑streaming conversion events and interest-based ad targeting to raise average order value (AOV) and reduce CAC.
• Regulatory & registration pathway: accelerate local product registrations in SEA markets to enable pharmacy and online marketplace listings-critical for OTC and infant nutrition categories.
• R&D commercialization: translate anti-aging research into limited-edition or premium SKUs with clearer clinical claims to justify price premiums.

• International revenue share (%) - tracking traction in SEA vs. China.
• Online DTC sales growth and customer retention (repeat purchase rate, LTV/CAC ratio).
• Gross margin by product line - especially infant nutrition vs. standard supplements.
• Number of product registrations/approvals in target SEA markets and time-to-listing.
• R&D milestones & patents filed/licensed from anti‑aging collaborations.